Product Description
MAT2203 – an oral and non-toxic encochleated form of amphotericin B (CAmB). This antifungal drug is the primary broad-spectrum treatment for immunocompromised patients. Unlike some other therapies, it doesn’t simply stop fungus from growing, but kills it entirely. Until now, amphotericin B has only been available through intravenous administration, which can lead to kidney or “renal” toxicity. (Sourced from: https://www.matinasbiopharma.com/lnc-technology/mat2203)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Matinas Biopharma Holdings
Company Location: BEDMINSTER NJ 07921
Company CEO: Jerome D. Jabbour
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Acute Lymphoid Leukemia|Vulvovaginitis|Candidiasis, Vulvovaginal|Communicable Diseases|Vaginal Diseases|Acute Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Candidiasis, Chronic Mucocutaneous|Candidiasis, Cutaneous
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CAMB | P2 |
Completed |
Candidiasis, Cutaneous|Candidiasis, Chronic Mucocutaneous |
2021-11-09 |
|
| MB-70006 | P2 |
Withdrawn |
Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2020-12-01 |
53% |
| ORACLE | P2 |
Withdrawn |
Communicable Diseases |
2019-10-01 |
23% |
| MB-70005 | P2 |
Completed |
Communicable Diseases|Vulvovaginitis|Candidiasis, Vulvovaginal|Vaginal Diseases |
2017-05-01 |